Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,181 to 3,200 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| GBC+PIPT vs Guideline Based Care: Number of Patients Referred to Physical Therapy | 106 of 1,192 77 of 1,069 | 1.7 points -0.6 to 3.9 | 2,261 | NCT02647658 Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients |
| GBC+PIPT vs Guideline Based Care: Number of Patients Undergoing Interventional Pain Procedures | 32 of 1,192 43 of 1,069 | -1.3 points -2.9 to 0.1 | 2,261 | NCT02647658 Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients |
| GBC+PIPT vs Guideline Based Care: Number of Patients Referred to Surgery Specialist | 38 of 1,192 44 of 1,069 | -0.9 points -2.5 to 0.6 | 2,261 | NCT02647658 Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients |
| GBC+PIPT vs Guideline Based Care: Number of Patients Who Had Back Surgery | 29 of 1,192 19 of 1,069 | 0.7 points -0.6 to 1.9 | 2,261 | NCT02647658 Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients |
| GBC+PIPT vs Guideline Based Care: Number of Patients Prescribed Opioids | 89 of 1,192 86 of 1,069 | -0.6 points -2.8 to 1.6 | 2,261 | NCT02647658 Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients |
| GBC+PIPT vs Guideline Based Care: Number of Patients With Orders for Diagnostic Imaging Tests | 74 of 1,192 73 of 1,069 | -0.6 points -2.7 to 1.4 | 2,261 | NCT02647658 Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients |
| GBC+PIPT vs Guideline Based Care: Number of Patients Referred to Other Rehabilitation or Pain Management Specialist | 45 of 1,192 26 of 1,069 | 1.3 points -0.1 to 2.8 | 2,261 | NCT02647658 Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients |
| Seqirus Quadrivalent Influenza Vaccine vs Comparator Quadrivalent Influenza Vaccine: Safety Endpoint: The Frequency of Serious Adverse Events (SAEs). | 8 of 1,692 2 of 560 | 0.1 points -0.8 to 0.6 | 2,252 | NCT02545543 A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age |
| Seqirus Quadrivalent Influenza Vaccine vs Comparator Quadrivalent Influenza Vaccine: serious adverse events | 8 of 1,692 2 of 560 | 0.1 points -0.8 to 0.6 | 2,252 | NCT02545543 A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age |
| Pneumosil vs Synflorix: deaths from any cause | 1 of 1,503 2 of 747 | -0.2 points -0.9 to 0.2 | 2,250 | NCT03197376 Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants |
| Pneumosil vs Synflorix: serious adverse events | 51 of 1,503 26 of 747 | -0.1 points -1.9 to 1.4 | 2,250 | NCT03197376 Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants |
| Vedolizumab 300 mg (UC) vs Vedolizumab 300 mg (CD): Number of Participants With at Least One Clinically Significant Electrocardiogram (ECG) Findings | 7 of 894 7 of 1,349 | 0.3 points -0.4 to 1.1 | 2,243 | NCT00790933 An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease |
| Fosaprepitant vs Aprepitant: A Complete Response (no Vomiting and no Use of Rescue Therapy) Overall (in the 120 Hours Following Initiation of Cisplatin). | 795 of 1,106 820 of 1,134 | -0.4 points -4.1 to 3.3 | 2,240 | NCT00619359 Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017) |
| No Text Message Reminder (Control) Arm vs Text Message Reminder Arm: Attendance at Breast Screening | 661 of 1,118 722 of 1,122 | -5.2 points -9.2 to -1.2 | 2,240 | NCT01977599 Are Text Message Reminders an Effective Intervention for Improving the Uptake of Breast Screening? |
| No Text Message Reminder (Control) Arm vs Text Message Reminder Arm: Mobile Prevalence | 435 of 1,118 456 of 1,122 | -1.7 points -5.8 to 2.3 | 2,240 | NCT01977599 Are Text Message Reminders an Effective Intervention for Improving the Uptake of Breast Screening? |
| Fosaprepitant vs Aprepitant: A Complete Response (no Vomiting and no Use of Rescue Therapy) in the Delayed Phase (25 to 120 Hours Following Initiation of Cisplatin). | 822 of 1,106 841 of 1,133 | 0.1 points -3.5 to 3.7 | 2,239 | NCT00619359 Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017) |
| Golytely vs Miralax-Gatorade Prep: Population Level Adenoma Detection Rate (ADR) | 383 of 1,139 364 of 1,100 | 0.5 points -3.4 to 4.4 | 2,239 | NCT03298945 Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens |
| Golytely vs Miralax-Gatorade Prep: Cancellation or No-show in Each Bowel Prep Arm | 358 of 1,139 330 of 1,100 | 1.4 points -2.4 to 5.2 | 2,239 | NCT03298945 Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens |
| Golytely vs Miralax-Gatorade Prep: Colonoscopy Completion Rate | 591 of 1,139 600 of 1,100 | -2.7 points -6.8 to 1.5 | 2,239 | NCT03298945 Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens |
| Golytely vs Miralax-Gatorade Prep: deaths from any cause | 7 of 1,139 4 of 1,100 | 0.3 points -0.4 to 0.9 | 2,239 | NCT03298945 Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens |
Code
curl "https://conductscience.org/api/comparisons/v1?page=160"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=160
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02647658-0c9f8424",
"title": "GBC+PIPT vs Guideline Based Care: Number of Patients Referred to Physical Therapy",
"summary": "106 of 1192 against 77 of 1069; risk difference 1.7 points, 95% interval -0.6 to 3.9; NCT02647658, Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients",
"record": "/library/comparisons/NCT02647658-0c9f8424",
"nct_id": "NCT02647658",
"kind": "outcome",
"participants": 2261,
"risk_difference": {
"value": 0.01689623997840295,
"lower": -0.005746110926008151,
"upper": 0.03932126138473607
},
"group_1": "106 of 1,192",
"group_2": "77 of 1,069",
"difference": "1.7 points",
"interval": "-0.6 to 3.9",
"trial_title": "Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients"
},
{
"id": "NCT02647658-59d09f01",
"title": "GBC+PIPT vs Guideline Based Care: Number of Patients Undergoing Interventional Pain Procedures",
"summary": "32 of 1192 against 43 of 1069; risk difference -1.3 points, 95% interval -2.9 to 0.1; NCT02647658, Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients",
"record": "/library/comparisons/NCT02647658-59d09f01",
"nct_id": "NCT02647658",
"kind": "outcome",
"participants": 2261,
"risk_difference": {
"value": -0.013378871302917487,
"lower": -0.028969265754322,
"upper": 0.0014985711559636263
},
"group_1": "32 of 1,192",
"group_2": "43 of 1,069",
"difference": "-1.3 points",
"interval": "-2.9 to 0.1",
"trial_title": "Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=161",
"request_id": "-OBe1-CMj18La5A0"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant